A Phase 2 interventional study of Vesatolimod and VRC07523LS in HIV-1-infection, sponsored by Gilead Sciences. Completed at 1 site in South Africa. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Have all the following laboratory values at the screening visit:
Key Exclusion Criteria:
Females with coinfection and/or as described below:
Have a history of any of the following:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1 (Days 0-28), participants will receive ART through Period. On Days 0 \& 14, participants will be administered VES 6mg orally and on Day 28, participants will be administered VES either 6 or 8mg orally. VRC07-523LS \& CAP256V2LS 20mg/kg will be administered intravenously on Day 7. In Period 2 (Days 29-133 or until ART restart), participants will discontinue ART at Day 35 and remain off ART until reaching ART restart criteria. Participants will receive VES 6 or 8mg orally every 2 weeks from Day 29 or until plasma HIV-1 RNA is \>=5000 copies/mL. In Period 3, (Days 134-336 or until ART restart), participants will continue ATI and no study treatment will be administered. In Period 4, (Days 337-413) participants who have not met ART restart criteria by Day 337 may choose to restart ART (Period 4a) or may choose to continue ATI until end of study (Period 4B). Any participants who meet ART restart criteria before the end of the study will remain in follow-up on ART (Period 4A).
Drug: Vesatolimod · Biological: VRC07523LS · Biological: CAP256V2LS
Administered orally
Also known as: GS-9620
Administered intravenously
Administered intravenously
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAE was defined as any AE that began on or after the study drug start date and no later than last exposure date after permanent discontinuation of study drug, or led to premature study drug discontinuation.
Time frame: Up to 61.1 weeks
Percentage of Participants Experiencing Treatment-emergent Graded Laboratory Abnormalities
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the last exposure date after permanent discontinuation of study drug. For maximum postbaseline toxicity grade, the most severe graded abnormality from all tests was counted for each participant. The severity grades were defined by Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, Antiviral Toxicity Grading Scale, Version 01 April 2015. The CTCAE v5 grading scale was used to grade AEs determined to be cytokine release syndrome and infusion-related reactions. The grading for both scales are as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-Threatening, Grade 5 = Death.
Time frame: Up to 61.1 weeks
Time to Viral Rebound (Confirmed ≥ 50 Copies/mL and ≥ 200 Copies/mL) Following ATI
Virologic rebound is defined as at any visit a rebound in HIV-1 RNA to ≥ 50 copies/mL or ≥ 200 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit. Time to rebound (in weeks) = (date of rebound or censoring date - ATI start date + 1) / 7.
Time frame: Up to 56 weeks
Change in Plasma Viral Load Set-point Following ATI
Change in plasma viral load set-point between pre-ART value and prior to ART reinitiation following ATI was summarized. The pre-ART set point value is the HIV-RNA load count prior to start of initial ARV treatment recorded in the clinical database.
Time frame: Pre-ART (Screening) and prior to ART reinitiation following ATI (Up to 56 weeks)
Change From Baseline of Viral Load at the End of ATI
Baseline value was the last available value collected on or prior to first dose of study drug.
Time frame: Up to 48 weeks
Time to ART Resumption Following ATI
Time to ART resumption (in weeks) = (date of restart ART after ATI period start or censoring date - ATI start date + 1) / 7.
Time frame: Up to 56 weeks
Pharmacokinetic (PK) Parameter of VES: Cmax
Cmax is defined as maximum observed concentration of drug.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: Tmax
Tmax is defined as time (observed time point) of Cmax.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: Clast
Clast is defined as last observed quantifiable concentration of the drug.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: Tlast
Tlast is defined as time (observed time point) of Clast.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: AUCinf
AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: AUClast
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: AUCexp
AUCexp is defined as AUC extrapolated between AUClast and AUCinf.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: t1/2
t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: CL/F
CL/F is defined as apparent clearance following extravascular administration.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VES: Vz/F
Vz/F is defined as apparent volume of distribution during the terminal phase following extravascular administration.
Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
PK Parameter of VRC07-523LS: Cmax
Cmax is defined as maximum observed concentration of drug.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: Tmax
Tmax is defined as time (observed time point) of Cmax.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: Clast
Clast is defined as last observed quantifiable concentration of the drug.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: Tlast
Tlast is defined as time (observed time point) of Clast.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: AUCinf
AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: AUClast
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: AUCexp
AUCexp is defined as AUC extrapolated between AUClast and AUCinf.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: t1/2
t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: Clearance (CL)
CL is defined as clearance following intravenous administration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: Vss
Vss is defined as the volume of distribution at steady-state following intravenous administration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of VRC07-523LS: Vz
Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: Cmax
Cmax is defined as maximum observed concentration of drug.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: Tmax
Tmax is defined as time (observed time point) of Cmax.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: Clast
Clast is defined as last observed quantifiable concentration of the drug.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: Tlast
Tlast is defined as time (observed time point) of Clast.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: AUCinf
AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: AUClast
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: AUCexp
AUCexp is defined as AUC extrapolated between AUClast and AUCinf.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: t1/2
t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: CL
CL is defined as clearance following intravenous administration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: Vz
Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
PK Parameter of CAP256V2LS: Vss
Vss is defined as the volume of distribution at steady-state after intravenous administration.
Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Percentage of Participants With Treatment-emergent Positive Anti-VRC07-523LS Antibodies
Time frame: Prebaseline (Day -13) up to Day 413
Percentage of Participants With Treatment-emergent Positive Anti-CAP256V2LS Antibodies
Time frame: Prebaseline (Day -13) up to Day 413
Participants were enrolled at a study site in South Africa.
| Milestone | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
An AE is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAE was defined as any AE that began on or after the study drug start date and no later than last exposure date after permanent discontinuation of study drug, or led to premature study drug discontinuation.
| percentage of participants | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | 95 |
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the last exposure date after permanent discontinuation of study drug. For maximum postbaseline toxicity grade, the most severe graded abnormality from all tests was counted for each participant. The severity grades were defined by Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, Antiviral Toxicity Grading Scale, Version 01 April 2015. The CTCAE v5 grading scale was used to grade AEs determined to be cytokine release syndrome and infusion-related reactions. The grading for both scales are as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-Threatening, Grade 5 = Death.
| percentage of participants | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| Any Grade 1 or Higher | 95 |
| Grade 1 | 20 |
| Grade 2 | 40 |
| Grade 3 | 35 |
| Grade 4 | 0 |
Virologic rebound is defined as at any visit a rebound in HIV-1 RNA to ≥ 50 copies/mL or ≥ 200 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit. Time to rebound (in weeks) = (date of rebound or censoring date - ATI start date + 1) / 7.
| weeks | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Confirmed ≥ 50 copies/mL | 11.00 (7.00 to 19.07) |
| Confirmed ≥ 200 copies/mL | 11.00 (7.00 to 19.14) |
Change in plasma viral load set-point between pre-ART value and prior to ART reinitiation following ATI was summarized. The pre-ART set point value is the HIV-RNA load count prior to start of initial ARV treatment recorded in the clinical database.
| log10 copies/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Change in Plasma Viral Load Set-point Following ATI | -1.42 (-1.85 to -0.77) |
Baseline value was the last available value collected on or prior to first dose of study drug.
| log10 copies/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Change From Baseline of Viral Load at the End of ATI | 2.96 (1.58 to 4.07) |
Time to ART resumption (in weeks) = (date of restart ART after ATI period start or censoring date - ATI start date + 1) / 7.
| weeks | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Time to ART Resumption Following ATI | 24.21 (12.64 to 47.14) |
Cmax is defined as maximum observed concentration of drug.
| pg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Pharmacokinetic (PK) Parameter of VES: Cmax | 6350 ± 4220 |
Tmax is defined as time (observed time point) of Cmax.
| hours (h) | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: Tmax | 2.00 (0.833 to 8.00) |
Clast is defined as last observed quantifiable concentration of the drug.
| pg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: Clast | 279 ± 177 |
Tlast is defined as time (observed time point) of Clast.
| h | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: Tlast | 48.0 (47.1 to 49.7) |
AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).
| h*pg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: AUCinf | 62700 ± 37700 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
| h*pg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: AUClast | 55500 ± 34200 |
AUCexp is defined as AUC extrapolated between AUClast and AUCinf.
| percent | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: AUCexp | 12.4 ± 6.68 |
t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
| h | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: t1/2 | 15.9 (10.4 to 27.0) |
CL/F is defined as apparent clearance following extravascular administration.
| Liters (L)/h | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: CL/F | 144 ± 112 |
Vz/F is defined as apparent volume of distribution during the terminal phase following extravascular administration.
| L | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VES: Vz/F | 3810 ± 3650 |
Cmax is defined as maximum observed concentration of drug.
| µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: Cmax | 481 ± 83.5 |
Tmax is defined as time (observed time point) of Cmax.
| h | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: Tmax | 0.550 (0.467 to 4.83) |
Clast is defined as last observed quantifiable concentration of the drug.
| µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: Clast | 3.51 ± 2.98 |
Tlast is defined as time (observed time point) of Clast.
| day | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: Tlast | 238 (147 to 336) |
AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).
| day*µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: AUCinf | 7540 ± 1360 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
| day*µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: AUClast | 7320 ± 1340 |
AUCexp is defined as AUC extrapolated between AUClast and AUCinf.
| percent | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: AUCexp | 2.94 ± 2.71 |
t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
| day | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: t1/2 | 41.9 (25.7 to 60.5) |
CL is defined as clearance following intravenous administration.
| L/day | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: Clearance (CL) | 0.198 ± 0.0513 |
Vss is defined as the volume of distribution at steady-state following intravenous administration.
| L | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: Vss | 11.5 ± 2.54 |
Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.
| L | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of VRC07-523LS: Vz | 12.0 ± 3.96 |
Cmax is defined as maximum observed concentration of drug.
| µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: Cmax | 644 ± 309 |
Tmax is defined as time (observed time point) of Cmax.
| h | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: Tmax | 1.50 (0.500 to 4.50) |
Clast is defined as last observed quantifiable concentration of the drug.
| µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: Clast | 1.52 ± 0.493 |
Tlast is defined as time (observed time point) of Clast.
| day | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: Tlast | 172 (126 to 321) |
AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).
| day*µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: AUCinf | 4290 ± 729 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
| day*µg/mL | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: AUClast | 4230 ± 710 |
AUCexp is defined as AUC extrapolated between AUClast and AUCinf.
| percent | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: AUCexp | 1.58 ± 0.452 |
t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
| day | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: t1/2 | 31.4 (20.2 to 77.8) |
CL is defined as clearance following intravenous administration.
| L/day | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: CL | 0.352 ± 0.116 |
Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.
| L | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: Vz | 15.3 ± 3.72 |
Vss is defined as the volume of distribution at steady-state after intravenous administration.
| L | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| PK Parameter of CAP256V2LS: Vss | 10.6 ± 2.21 |
| percentage of participants | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Percentage of Participants With Treatment-emergent Positive Anti-VRC07-523LS Antibodies | 15.0 |
| percentage of participants | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Percentage of Participants With Treatment-emergent Positive Anti-CAP256V2LS Antibodies | 55 |
Collected over All-Cause Mortality and Adverse Events: Up to 61.1 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VRC07-523LS + CAP256V2LS + VES | 0/20 (0%) | 2/20 (10%) | 19/20 (95%) |
| Event | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| CellulitisInfections and infestations | 1/20 |
| OverdoseInjury, poisoning and procedural complications | 1/20 |
| Intentional self-injuryPsychiatric disorders | 1/20 |
| Event | VRC07-523LS + CAP256V2LS + VES |
|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 18/20 |
| HeadacheNervous system disorders | 14/20 |
| TachycardiaCardiac disorders | 8/20 |
| PyrexiaGeneral disorders | 7/20 |
| Haemoglobin decreasedInvestigations | 7/20 |
| NauseaGastrointestinal disorders | 5/20 |
| Chest discomfortGeneral disorders | 5/20 |
| FatigueGeneral disorders | 4/20 |
| Upper respiratory tract infectionInfections and infestations | 4/20 |
| AnaemiaBlood and lymphatic system disorders | 3/20 |
The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 20 |
| >=65 years | 0 |
| Age, Continuous(years) | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| Mean | 27 ± 2.4 |
| Sex: Female, Male(Participants) | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| Female | 20 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 20 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | VRC07-523LS + CAP256V2LS + Vesatolimod (VES) |
|---|---|
| South Africa | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Jan 2025, 31 months.
Results were first posted in Jan 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VRC07-523LS